We aim to identify novel molecules targeting pro-survival pathways in dopamine neurons, which can be used as potential therapies for Parkinson’s disease treatment. For example, we have shown that microRNA biogenesis pathways play a crucial role in dopamine neuron maintenance and its pharmacological stimulation promotes survival of dopamine neurons.
We have expertise in developing transgenic rodent models, as well as in design, production, and application of lentiviral vectors for specific expression of transgenes and CRISPR/Cas9-mediated genome editing in brain cells and neuronal progenitors.
Our main research directions are:
Andrii Domanskyi, PhD, Docent
Institute of Biotechnology, HiLIFE
Biocenter 2, room 6028b
P.O. Box 56 (Viikinkaari 5D)
00014 University of Helsinki
Office: +358 2941 59654 / +358 50 4484545
Andrii is a Visiting Scholar at BI.